Sanofi-Aventis' obesity pill, Acomplia, won't qualify for reimbursement in Germany after a Berlin court rejected a suit by the French company seeking to remove its status as a ``lifestyle'' drug.
The court confirmed a decision by a panel of doctors and insurers last year to classify the medicine as one that shouldn't be reimbursed under the public-health system because it isn't deemed vital for treating a disease, according to a statement on the government panel's Web site today.
Paris-based Sanofi had attempted to reverse the panel's decision.
More at Bloomberg
No comments:
Post a Comment